Why the study?
The study was conducted to evaluate the therapeutic potential of fluoxetine in pulmonary arterial hypertension.
Does fluoxetine improve pulmonary vascular resistance in patients with pulmonary arterial hypertension?
Does fluoxetine improve pulmonary vascular resistance in patients with pulmonary arterial hypertension?
Fluoxetine therapy for 12 to 24 weeks did not improve pulmonary vascular resistance or other hemodynamics in patients with pulmonary arterial hypertension.
Answers are grounded in this paper and cite their sources.
Should not prompt fluoxetine prescribing in PAH; leaves open whether RCTs could demonstrate hemodynamic benefit.
In order to evaluate the therapeutic potential of fluoxetine in pulmonary arterial hypertension, 13 patients with pulmonary arterial hypertension underwent catheterization before and after 12 (N = 5) or 24 (N = 8) weeks fluoxetine therapy. No change was seen in the primary endpoint of pulmonary vascular resistance, other hemodynamic values, or any secondary endpoints.
No takes yet. Share an insight, caveat, or question.
Sodimu et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: